Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users (Q33183396)

23 July 2017

Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users (English)

1 reference

23 July 2017

1 reference

1 reference

1 reference

Bourlière M

1

1 reference

23 July 2017

Barberin JM

2

1 reference

23 July 2017

Rotily M

3

1 reference

23 July 2017

Guagliardo V

4

1 reference

23 July 2017

Portal I

5

1 reference

23 July 2017

Lecomte L

6

1 reference

23 July 2017

Benali S

7

1 reference

23 July 2017

Boustière C

8

1 reference

23 July 2017

Perrier H

9

1 reference

23 July 2017

Jullien M

10

1 reference

23 July 2017

Lambot G

11

1 reference

23 July 2017

Loyer R

12

1 reference

23 July 2017

LeBars O

13

1 reference

23 July 2017

Daniel R

14

1 reference

23 July 2017

Khiri H

15

1 reference

23 July 2017

Halfon P

16

1 reference

23 July 2017

1 January 2002

1 reference

Journal of Viral Hepatitis

23 July 2017

1 reference

23 July 2017

9

1 reference

23 July 2017

1

1 reference

23 July 2017

62-70

1 reference

Hepatitis viruses: changing patterns of human disease

23 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

The molecular biology of hepatitis C virus. Genotypes and quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Variability of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

A proposed system for the nomenclature of hepatitis C viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Hepatitis C virus genotypes in French blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Clinical significance of hepatitis C virus genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Factors predictive of a beneficial response to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

The influence of age on the prevalence of hepatitis C virus subtypes 1a and 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Tattooing as a risk of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Hepatitis C virus infection in dialysis and renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Patient-to-patient transmission of hepatitis C virus during colonoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Hepatitis C virus seroconversion rate in a hyperendemic area of HCV in Japan: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Sporadic hepatitis C virus infection: a case-control study of transmission routes in a selected hospital sample of the general population in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00319.X

10.1046/J.1365-2893.2002.00319.X

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference